


PRODUCT INFORMATION



Rosiglitazone

Item No. 71740

CAS Registry No.: 122320-73-4
Formal Name: 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]-2,4-thiazolidinedione
Synonym: BRL 49653
MF: C₁₈H₁₉N₃O₃S
FW: 357.4
Purity: ≥98%
UV/Vis.: λ_{max}: 248, 311 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Rosiglitazone is supplied as a crystalline solid. A stock solution may be made by dissolving the rosiglitazone in the solvent of choice, which should be purged with an inert gas. Rosiglitazone is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide. The solubility of rosiglitazone in these solvents is approximately 1, 34, and 25 mg/ml, respectively.

Rosiglitazone is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, rosiglitazone should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Rosiglitazone has a solubility of approximately 0.5 mg/ml in a 1:3 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Rosiglitazone is an agonist of peroxisome proliferator-activated receptor γ (PPAR γ).¹ It activates PPAR γ 1 and PPAR γ 2 in reporter assays (EC₅₀s = 30 and 100 nM, respectively). Rosiglitazone selectively activates chimeras containing the ligand-binding domains (LBDs) of PPAR γ over PPAR α and PPAR δ in a cell-based reporter assay at 10 nM. It induces differentiation of C3H10T1/2 stem cells into adipocytes when used at a concentration of 1 μ M. Rosiglitazone is also an inhibitor of long-chain acyl-CoA synthetase 4 (ACSL4; IC₅₀ = 0.5 μ M).^{2,3} It inhibits RSL3-induced ferroptosis in Gpx4 Cre-lox-expressing mouse embryonic fibroblasts (Pfa1) cells and Pparg knockout (KO) cells and increases survival in a Gpx4 KO mouse model of ferroptosis when used at a concentration of 0.0125 mg/ml in the drinking water. It decreases hemoglobin A1c (HbA1c) and fasting blood glucose levels in a rat model of type 2 diabetes induced by streptozotocin (STZ; Item No. 13104) and a high-carbohydrate and high-fat diet when administered at a dose of 4 mg/kg.⁴ Formulations containing rosiglitazone have been used to improve glycemic control in the treatment of type 2 diabetes.

References

1. Lehmann, J.M., Moore, L.B., Smith-Oliver, T.A., et al. *J. Biol. Chem.* **270**(22), 12953-12956 (1995).
2. Kim, J.-H., Lewin, T.M., and Coleman, R.A. *J. Biol. Chem.* **276**(27), 24667-24673 (2001).
3. Doll, S., Proneth, B., Tyurina, Y.Y., et al. *Nat. Chem. Biol.* **13**(1), 91-98 (2017).
4. Zhou, J.Y., Zhou, S.W., Zhang, K.B., et al. *Biol. Pharm. Bull.* **31**(6), 1169-1176 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/28/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM